Full TitlePhase I/Ib Study of Crenolanib with Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma
Treatment with the anticancer drugs ramucirumab and paclitaxel is a standard approach for patients with advanced cancer of the esophagus, gastroesophageal junction (the area where the esophagus meets the stomach), and stomach. However, in most patients who receive this treatment, the cancer eventually continues to grow.
In this study, researchers are assessing the safety and effectiveness of adding crenolanib to ramucirumab/paclitaxel therapy in patients with advanced esophageal, gastroesophageal, and stomach cancers. Crenolanib is an investigational drug designed to inhibit the growth of the blood vessels that tumors need to grow and spread. It is taken orally (by mouth), while ramucirumab and paclitaxel are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have advanced esophageal, gastroesophageal, or stomach cancer that has continued to grow despite one previous treatment.
- At least 2 weeks must pass between the completion of chemotherapy or immunotherapy and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Geoffrey Ku at 646-888-4588.